Abstract

Purpose – to investigate the dynamics of heart rhythm variability (HRV) in patients with type 2 DM who have had non-Q-MI, during treatment with ALA and Zn sulfate.Materials and methods. 49 patients were examined (mean age 60,97±1,59 years) with type 2 DM who have had non-Q-MI. In addition to basic treatment patients received ALA 600 mg/day and Zn sulfate 248 mg/day for 4 months. 24-hour ECG monitoring with HRV evaluation was performed before treatment and after its completion.Results and discussion. Analysis of statistical rates of HRV in patients with type 2 DM who have had non-Q-MI after 4 months of ALA with Zn sulfate supplementation revealed a tendency to increase daytime RMSSD (p<0,2), daytime and nocturnal pNN50% (p<0,2). Concerning spectral rates of HRV in the daytime period of observation there was increase in highfrequency activity of HF (p<0.01), HFnorm (p<0,001) with increase in its contribution to the total spectral power HF% (p<0,001). It was also recorded a decrease in the percentage of low-frequency LFnorm% (p<0,001) and the growth of high-frequency HFnorm% (p<0,001) activity, which was reflected in sympathovagal interaction ratio LF/HF (p<0,001). In the night time it was also recorded reduction in LF/HF (p<0,05).Conclusions. The use of ALA and Zn sulfate for 4 months in patients with type 2 DM who have had MI, has a positive effect on heart rhythm variability, increasing the tone of autonomic nervous system and normalizing sympathovagal interaction.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call